BioSpace News Archive

Panbela Therapeutics, Inc. today announced it has divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds ® 1 (USWM), a Kentucky-based specialty pharmaceutical company.

A simple, finger prick blood test — not so different from what people with diabetes do every day — shows promise in the ability to detect Alzheimer’s disease, according to research reported for the first time today at the Alzheimer’s Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online.

Inspira Technologies OXY B.H.N. Ltd. announced today that it has entered into a collaboration agreement with Perfusion Solution, Inc. (“Perfusion Solution”).

Velia Inc. a biotechnology company pioneering the therapeutic potential within the dark matter of the human proteome, backed by The Column Group and Foresite Capital, today announced the appointment of industry leader John McHutchison, AO, MD as President and Chief Executive Officer.

First Wave BioPharma, Inc. today announced the pricing of a public offering of 3,285,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 6,570,000 shares of its common stock.

Inozyme Pharma, Inc. today announced that it will host a conference call to provide an update on the Company’s ENPP1 Deficiency program on July 26, 2023, at 8am ET.

Tenax Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for oral levosimendan (TNX-103) in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), expiring in 2040.

Schrödinger will report its second quarter 2023 financial results on Wednesday, August 2, 2023, after the financial markets close.

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place in Brisbane, Australia, and virtually, from July 23-26, 2023.